Home/Pipeline/GEn-1124

GEn-1124

Acute Respiratory Distress Syndrome (ARDS)

Phase 2Active

Key Facts

Indication

Acute Respiratory Distress Syndrome (ARDS)

Phase

Phase 2

Status

Active

Company

GEn1E Lifesciences

About GEn1E Lifesciences

GEn1E Lifesciences is a private, clinical-stage biotech accelerating first-in-class therapies for inflammatory and rare diseases. Its lead asset, GEn-1124, is a dual p38α:MK2 signal modulator in Phase 2 for ARDS, developed in collaboration with BARDA. The company's core differentiator is its GRID™ AI platform, which enables rapid identification of novel allosteric binding pockets and has propelled its lead program from discovery to Phase 2 in just 2.5 years using seed capital.

View full company profile

Therapeutic Areas

Inflammatory Diseases Rare Diseases Respiratory Immuno-oncology

Other Acute Respiratory Distress Syndrome (ARDS) Drugs

Drug	Company	Phase	Status
MultiStem	Athersys	Phase 3	Active (subject to funding)
BXT-25	BioXyTran	Preclinical	Active
Bioengineered Surfactant Program	BioSuperior	Pre-clinical	Active
FX06	F4 Pharma	Phase 1/2	Active
AVM0703	AVM Biotechnology	Pre-clinical / Research	Active
ACE2v2-Fc	Cyrus Biotechnology	Preclinical	Active
AZM-152	Azome Therapeutics	Pre-clinical	Active
Zelpultide Alfa	Airway Therapeutics	Pre-clinical/Research	Active
ALT-100 mAb	Aqualung Therapeutics	Phase 2a	Active
RP-323	PhorMed	Phase 2	Active
Research Grant: Effect of volatile sedation on spontaneous breathing in ARDS	Sedana Medical	Investigator-Initiated Trial	Active
Research Grant: Effects of sevoflurane on lung water in ARDS	Sedana Medical	Investigator-Initiated Trial	Active